Skip to main content

Table 3 Summary of patient demographic and clinicopathological profiles.

From: Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

Characteristic

Number of Patients

ALK fusion

  

Positive

Negative

P -value

No. of patients

103

12 (11.6%)

91

 

Age (years; mean ± SD)

52 (< 61 y)

8

44

0.37

 

53 (≥ 61 y)

4

39

 

Gender

    

   Male

74 (71.8%)

7

67

0.27

   Female

29 (28.2%)

5

24

 

Smoking

    

   Smokers

51 (49.5%)

2

47

0.03

   Non-smokers

52 (50.5%)

10

44

 

Histology

    

   Adenocarcinoma

62 (60.2%)

10

52

0.08*

   Squamous cell

29 (28.1%)

2

27

 

carcinoma

11 (10.7%)

0

11

 

   Large-cell

1 (1.0%)

0

1

 

carcinoma

    

   Others

    

Stage

    

   I

63 (61.2%)

8

55

0.72

   II

18 (17.5%)

1

17

 

   III

20 (19.4%)

3

17

 

   IV

2 (1.9%)

0

2

 
  1. * AC compared with combined SCC, LCC, and other histological types.
Back to article page

Molecular Cancer

ISSN: 1476-4598